Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
07:15pm, Friday, 23'rd Jan 2026
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
11:36am, Thursday, 15'th Jan 2026
PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:55pm, Monday, 12'th Jan 2026
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models The planned collaboration highlights the role of complete genome resolution in scaling
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
09:05am, Monday, 12'th Jan 2026
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio's Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families Trios from 200 families
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities
12:21pm, Friday, 09'th Jan 2026
PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material Community-developed approach combines multi-contact 3C
Here's Why You Should Add PacBio Stock to Your Portfolio
01:10pm, Wednesday, 07'th Jan 2026
PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.
Three Genomics Stocks Worth Tracking This Year
08:11am, Tuesday, 06'th Jan 2026
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up – Time to Buy?
02:27am, Sunday, 04'th Jan 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) shares gapped up before the market opened on Friday. The stock had previously closed at $1.87, but opened at $1.95. Pacific Bio
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 30'th Dec 2025
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenti
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.1% – Should You Sell?
02:55am, Sunday, 28'th Dec 2025
Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) dropped 5.1% during trading on Friday. The stock traded as low as $1.79 and last traded at $1.7850. Approximately 1,8
